Abstract: The present disclosure provides, in part, compositions comprising an antibody or antibody fragment that immunospecifically binds to MCH class I polypeptide-related sequence A (MICA), or an epitope thereof.

Abstract: The present disclosure provides, in part, methods of discovering immunotherapy targets in vivo, therapeutic compositions (e.g., shRNA, immunoresponsive cells expressing shRNA and/or a chimeric antigen receptors (CAR)), and methods of use thereof.

Abstract: The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

Abstract: The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

Abstract: The present invention relates to novel compositions and methods for the generation of MHC class II compounds. Such methods are useful in identifying antigen-specific T cells, regulating an immune response and treating subjects suffering from an immune disorder.

Abstract: Methods and compositions for diagnosing and treating autoimmune disease, e.g., acute disseminated encephalomyelitis (ADEM), are described.

Abstract: The invention provides classes of novel compounds that accelerate peptide loading to DR in the absence of DM and related pharmaceutical compositions. The invention also provides conjugates of these compounds with peptides, antigens or other MHC-based therapeutics, including peptides that self-catalyze their loading onto MHC Class II molecules. Methods are provided for modulating an immune response in a subject. Also disclosed are methods of using the novel compounds, e.g., in combination with MHC-based therapeutics, for the treatment of autoimmune diseases and for the manufacture of medicaments. Methods of improving loading of viral peptides and tumor peptides for enhancing the CD4 T cell response following vaccination against viruses or tumors, and related vaccines, are also provided.

Abstract: Methods and compositions for diagnosing and treating autoimmune disease, e.g., acute disseminated encephalomyelitis (ADEM), are described.

Abstract: The present invention provides isolated peptides relating to the autoimmune diseases pemphigus vulgaris and multiple sclerosis. The peptides relating to pemphigus vulgaris are self epitopes and those relating to multiple sclerosis are foreign antigens derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharamaceutical preparations for tolerizing and/or immunizing individuals are provided as well as methods relating thereto. Methods are provided for identifying other self and non-self epitopes involved in human autoimmune disease and similar pharamaceutical preparations and methods of use for these epitopes are also provided.

Abstract: The present invention relates to novel compositions and methods for the generation of MHC class II compounds. Such methods are useful in identifying antigen-specific T cells, regulating an immune response and treating subjects suffering from an immune disorder.

Abstract: The present invention provides isolated peptides relating to the autoimmune diseases pemphigus vulgaris and multiple sclerosis. The peptides relating to pemphigus vulgaris are self epitopes and those relating to multiple sclerosis are foreign antigens derived from human pathogens which are implicated in the aetiology and remissions of the disease. Pharamaceutical preparations for tolerizing and/or immunizing individuals are provided as well as methods relating thereto. Methods are provided for identifying other self and non-self epitopes involved in human autoimmune disease and similar pharamaceutical preparations and methods of use for these epitopes are also provided.